Ultra Market Research | United States Obesity Drugs Market
United States Obesity Drugs Market
Report ID : 784
Category : Pharmaceuticals,United-States(US)
No Of Pages : 176
Published on: October 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The United States obesity drugs market has emerged as a critical sector in addressing the rising obesity rates, as millions of Americans battle obesity and its related health issues, including diabetes, hypertension, and cardiovascular disease. The market includes a wide range of FDA-approved weight loss medications targeting various mechanisms to aid in weight management and fat reduction. In recent years, increased awareness of the health risks associated with obesity has led to a surge in demand for prescription-based anti-obesity drugs. With a market size of over $1.6 billion in 2023, the obesity treatment drugs market in the U.S. is on an upward trajectory, driven by new drug introductions, ongoing research in weight management drugs, and an evolving FDA approval landscape. Key trends in the United States obesity drugs market include an emphasis on innovation in pharmacotherapy and increased consumer interest in safe and effective weight loss solutions.
Segmentation
By Drug Class
Appetite Suppressants
Sympathomimetic Appetite Suppressants
Non-Sympathomimetic Appetite Suppressants
Lipase Inhibitors
Orlistat-based Drugs
Others
Serotonin Receptor Agonists
Lorcaserin-based Drugs
Others
Combination Drugs
Phentermine-Topiramate
Naltrexone-Bupropion
By End-Use Application
Healthcare Facilities
Hospitals
Public Hospitals
Private Hospitals
Specialized Obesity Centers
Clinics
Bariatric Clinics
General Clinics
Weight Loss Centers
Non-Surgical Weight Loss Centers
Medically Supervised Weight Loss Programs
By Distribution Channel
Retail Pharmacies
Chain Pharmacies
National Chains
Regional Chains
Independent Pharmacies
Online Pharmacies
Prescription Fulfillment Platforms
Drug Manufacturer Websites
Hospital Pharmacies
By Prescription Type
Prescription-only Weight Loss Drugs
Oral Tablets
Extended Release Capsules
Others
Over-the-counter (OTC) Drugs
Herbal Supplements
Appetite Suppressants
List of Market Players
Novo Nordisk (Denmark)
Eli Lilly and Company (United States)
Pfizer Inc. (United States)
AstraZeneca PLC (United Kingdom)
Merck & Co., Inc. (United States)
GlaxoSmithKline PLC (United Kingdom)
Allergan, Inc. (United States)
Roche Holding AG (Switzerland)
Sanofi (France)
Vivus, Inc. (United States)
Bausch Health Companies Inc. (Canada)
Zafgen, Inc. (United States)
Orexigen Therapeutics, Inc. (United States)
Arena Pharmaceuticals, Inc. (United States)
Johnson & Johnson (United States)
Drivers
Increasing Obesity Rates: The prevalence of obesity in the United States continues to rise, leading to a high demand for effective obesity treatment options.
Health Risks Associated with Obesity: With obesity being linked to severe health conditions like cardiovascular disease and type 2 diabetes, there is an increased urgency for obesity treatments.
New Drug Approvals: The FDA’s support for weight management drugs and approval of novel drugs have bolstered market expansion.
Public Awareness: Growing awareness of obesity and its effects, fueled by government and healthcare initiatives, has led more people to seek prescription weight-loss medications.
Rise in Preventive Healthcare: Consumers are increasingly adopting preventive measures, including weight loss drugs, to avoid long-term health issues associated with obesity.
Restraints
High Cost of Obesity Drugs: Prescription weight loss medications can be costly, limiting access for many consumers without adequate insurance.
Side Effects of Anti-Obesity Drugs: Some obesity drugs are associated with side effects, affecting patient adherence and acceptance of these treatments.
Regulatory Challenges: Stringent regulatory policies by the FDA regarding drug safety and efficacy impact the pace at which new drugs enter the market.
Social Stigma: Social stigmas surrounding obesity may prevent individuals from seeking medical intervention, thereby limiting market growth.
Lack of Insurance Coverage: Some insurance providers do not cover weight loss medications, making it difficult for patients to afford ongoing treatments.
Opportunity
Innovation in Drug Formulation: The development of new formulations, such as combination therapies and injectable drugs, offers growth potential for the market.
Increased Research Funding: Ongoing research and development in weight management therapies are backed by significant funding from both public and private sectors.
Growing Demand for Personalized Medicine: Personalized medicine, including tailored obesity treatments, offers an untapped market opportunity in the U.S.
Expansion in Digital Healthcare: The rise of telemedicine and online consultations facilitates patient access to prescription obesity drugs.
Rising Focus on Preventive Healthcare: Preventive healthcare measures are gaining popularity, creating opportunities for the obesity drugs market.
Trend
There is a growing focus on developing combination obesity drugs in the United States obesity drugs market, with companies investing heavily in research to formulate drugs that tackle multiple mechanisms of obesity management simultaneously. Recent trends also highlight a significant increase in the use of injectable therapies, providing longer-lasting effects and improved efficacy over oral drugs. The United States obesity drugs market is also witnessing a shift toward personalized weight loss treatments, where drug prescriptions are tailored based on genetic and metabolic factors. Additionally, the rise of digital health platforms and telemedicine has made it easier for patients to access prescriptions and manage weight loss programs under professional supervision. Partnerships between pharmaceutical companies and digital health firms aim to offer integrated healthcare solutions, which not only improve patient adherence but also support weight management through virtual consultations and lifestyle management tools.
Key Target Audience
Hospitals and Clinics Weight Loss Centers Retail and Online Pharmacies Health Insurance Providers Pharmaceutical and Biotechnology Companies Healthcare Research Institutes Healthcare and Wellness Service Providers Government Health Departments
FAQs about the United States Obesity Drugs Market
The market comprises prescription and over-the-counter drugs developed to assist with weight management and obesity treatment.
Novo Nordisk, Eli Lilly, Pfizer, and GlaxoSmithKline are prominent players in the U.S. obesity drugs market.
Rising obesity rates, increased awareness of obesity risks, and new FDA-approved drugs drive the market.
Insurance coverage varies by provider, with many plans still not covering obesity medications.
Personalized treatments, combination therapies, and increased use of injectable drugs define current trends in the market.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis 2. Market Dashboard 3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Drug Class 3.2.2 By End-Use Application 3.2.3 By Distribution Channel 3.2.4 By Prescription Type 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges 4. United States Obesity Drugs Market by Drug Class 4.1 Introduction 4.2 Market Size and Growth Rate by Drug Class (2024-2030) 4.2.1 Appetite Suppressants 4.2.1.1 Sympathomimetic Appetite Suppressants 4.2.1.2 Non-Sympathomimetic Appetite Suppressants 4.2.2 Lipase Inhibitors 4.2.2.1 Orlistat-based Drugs 4.2.2.2 Others 4.2.3 Serotonin Receptor Agonists 4.2.3.1 Lorcaserin-based Drugs 4.2.3.2 Others 4.2.4 Combination Drugs 4.2.4.1 Phentermine-Topiramate 4.2.4.2 Naltrexone-Bupropion 5. United States Obesity Drugs Market by End-Use Application 5.1 Introduction 5.2 Market Size and Growth Rate by End-Use Application (2024-2030) 5.2.1 Healthcare Facilities 5.2.1.1 Hospitals 5.2.1.1.1 Public Hospitals 5.2.1.1.2 Private Hospitals 5.2.1.1.3 Specialized Obesity Centers 5.2.1.2 Clinics 5.2.1.2.1 Bariatric Clinics 5.2.1.2.2 General Clinics 5.2.2 Weight Loss Centers 5.2.2.1 Non-Surgical Weight Loss Centers 5.2.2.2 Medically Supervised Weight Loss Programs 6. United States Obesity Drugs Market by Distribution Channel 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 6.2.1 Retail Pharmacies 6.2.1.1 Chain Pharmacies 6.2.1.1.1 National Chains 6.2.1.1.2 Regional Chains 6.2.1.2 Independent Pharmacies 6.2.2 Online Pharmacies 6.2.2.1 Prescription Fulfillment Platforms 6.2.2.2 Drug Manufacturer Websites 6.2.3 Hospital Pharmacies 7. United States Obesity Drugs Market by Prescription Type 7.1 Introduction 7.2 Market Size and Growth Rate by Prescription Type (2024-2030) 7.2.1 Prescription-only Weight Loss Drugs 7.2.1.1 Oral Tablets 7.2.1.2 Extended Release Capsules 7.2.1.3 Others 7.2.2 Over-the-counter (OTC) Drugs 7.2.2.1 Herbal Supplements 7.2.2.2 Appetite Suppressants 7.2.3 Others 8. Competitive Landscape 8.1 Company Profiles 8.1.1 Novo Nordisk (Denmark) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.2 Eli Lilly and Company (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.3 Pfizer Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.4 AstraZeneca PLC (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.5 Merck & Co., Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.6 GlaxoSmithKline PLC (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.7 Allergan, Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.8 Roche Holding AG (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.9 Sanofi (France) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.10 Vivus, Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.11 Bausch Health Companies Inc. (Canada) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.12 Zafgen, Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.13 Orexigen Therapeutics, Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.14 Arena Pharmaceuticals, Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.15 Johnson & Johnson (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9. List of Tables and Figures List of Tables Table United States Obesity Drugs Market Size by Drug Class (2024-2030) Table Appetite Suppressants Market Size by Sub-type (2024-2030) Table Lipase Inhibitors Market Size by Sub-type (2024-2030) Table Serotonin Receptor Agonists Market Size by Sub-type (2024-2030) Table Combination Drugs Market Size by Sub-type (2024-2030) Table United States Obesity Drugs Market Size by End-Use Application (2024-2030) Table Healthcare Facilities Market Size by Sub-type (2024-2030) Table Weight Loss Centers Market Size by Sub-type (2024-2030) Table United States Obesity Drugs Market Size by Distribution Channel (2024-2030) Table Retail Pharmacies Market Size by Sub-type (2024-2030) Table Online Pharmacies Market Size by Sub-type (2024-2030) Table Hospital Pharmacies Market Size (2024-2030) Table United States Obesity Drugs Market Size by Prescription Type (2024-2030) Table Prescription-only Weight Loss Drugs Market Size by Sub-type (2024-2030) Table Over-the-counter (OTC) Drugs Market Size by Sub-type (2024-2030) List of Figures Figure United States Obesity Drugs Market Size and Growth Rate by Drug Class (2024-2030) Figure Appetite Suppressants Market Growth Rate by Sub-type (2024-2030) Figure Lipase Inhibitors Market Growth Rate by Sub-type (2024-2030) Figure Serotonin Receptor Agonists Market Growth Rate by Sub-type (2024-2030) Figure Combination Drugs Market Growth Rate by Sub-type (2024-2030) Figure United States Obesity Drugs Market Size and Growth Rate by End-Use Application (2024-2030) Figure Healthcare Facilities Market Growth Rate by Sub-type (2024-2030) Figure Weight Loss Centers Market Growth Rate by Sub-type (2024-2030) Figure United States Obesity Drugs Market Size and Growth Rate by Distribution Channel (2024-2030) Figure Retail Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure Online Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure Hospital Pharmacies Market Growth Rate (2024-2030) Figure United States Obesity Drugs Market Size and Growth Rate by Prescription Type (2024-2030) Figure Prescription-only Weight Loss Drugs Market Growth Rate by Sub-type (2024-2030) Figure Over-the-counter (OTC) Drugs Market Growth Rate by Sub-type (2024-2030)
Tables Financial Overview of Key Companies Table Novo Nordisk Obesity Drugs Financial Overview Table Eli Lilly and Company Obesity Drugs Financial Overview Table Pfizer Inc. Obesity Drugs Financial Overview Table AstraZeneca PLC Obesity Drugs Financial Overview Table Merck & Co., Inc. Obesity Drugs Financial Overview Table GlaxoSmithKline PLC Obesity Drugs Financial Overview Table Allergan, Inc. Obesity Drugs Financial Overview Table Roche Holding AG Obesity Drugs Financial Overview Table Sanofi Obesity Drugs Financial Overview Table Vivus, Inc. Obesity Drugs Financial Overview Table Bausch Health Companies Inc. Obesity Drugs Financial Overview Table Zafgen, Inc. Obesity Drugs Financial Overview Table Orexigen Therapeutics, Inc. Obesity Drugs Financial Overview Table Arena Pharmaceuticals, Inc. Obesity Drugs Financial Overview Table Johnson & Johnson Obesity Drugs Financial Overview
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macroeconomic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United States market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States Obesity Drugs Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue United Statesly. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United States Obesity Drugs Market for the past year and forecasts for the next six years. United States United States Obesity Drugs Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States Obesity Drugs Market Market categories. Market size and forecasts for each major application is provided in the context of United States market. The numbers provided in this report are derived on the basis of demand for United States Obesity Drugs Market from different application industries in different regions.
